Ocular Aesthetics

Ocular Aesthetics was a private clinical-stage biotechnology company focused on developing topical treatments for the aesthetic improvement of the eye. The company's lead program was a first-in-class topical formulation designed to reduce ocular redness and enhance the whiteness of the sclera for cosmetic purposes. Founded by a team of prominent ophthalmologists, the company aimed to address the growing consumer demand for medical-grade aesthetic eye care. In October 2015, Ocular Aesthetics was acquired by Allergan, which sought to integrate the technology into its market-leading ophthalmology and medical aesthetics portfolios. This acquisition allowed Allergan to expand its footprint in the emerging aesthetic eye care market, complementing its existing products like Latisse.